GSK Gets Warning Letter For Omissions In Reporting Requirements
This article was originally published in The Pink Sheet Daily
Executive Summary
Observations from FDA’s routine inspection primarily cite omissions from periodic reports from Avandia clinical trials.
You may also be interested in...
FDA's Warning On Postmarketing Adverse Event Reporting To Actelion Signals Enforcement Trend
While still much less frequent than GMP warning letters, PADE letters are on the rise, with FDA focusing on reports for drugs with known serious safety issues.
FDA's Warning On Postmarketing Adverse Event Reporting To Actelion Signals Enforcement Trend
While still much less frequent than GMP warning letters, PADE letters are on the rise, with FDA focusing on reports for drugs with known serious safety issues.
Avandia Expands Black Box With Heart Attack Risk Information
FDA revises labeling for all oral anti-diabetics to include warning about the absence of conclusive evidence of cardiovascular risk.